Skip to main content
×
×
Home

Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs

  • Simone N. Vigod (a1), Yona Lunsky (a2), Virginie Cobigo (a3), Andrew S. Wilton (a4), Sarah Somerton (a5) and Dallas P. Seitz (a6)...
Abstract
Background

While up to 45% of individuals with intellectual and developmental disabilities (IDD) have a comorbid psychiatric disorder, and antipsychotics are commonly prescribed, gender differences in the safety of antipsychotics have rarely been studied in this population.

Aims

To compare men and women with IDD on medical outcomes after antipsychotic initiation.

Method

Our population-based study in Ontario, Canada, compared 1457 women and 1951 men with IDD newly initiating antipsychotic medication on risk for diabetes mellitus, hypertension, venous thromboembolism, myocardial infarction, stroke and death, with up to 4 years of follow-up.

Results

Women were older and more medically complex at baseline. Women had higher risks for venous thromboembolism (HR 1.72, 95% CI 1.15–2.59) and death (HR 1.46, 95% CI 1.02–2.10) in crude analyses; but only thromboembolism risk was greater for women after covariate adjustment (aHR 1.58, 95% CI 1.05–2.38).

Conclusions

Gender should be considered in decision-making around antipsychotic medications for individuals with IDD.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
      Available formats
      ×
Copyright
This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Corresponding author
Simone Vigod, Women's Mental Health Program, Women's College Hospital, 76 Grenville Street Room 7234, Toronto, Ontario M5S 1B2, Canada. Email: simone.vigod@wchospital.ca
Footnotes
Hide All

Declaration of interest

None.

Copyright and usage

© The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence.

Footnotes
References
Hide All
1 Lunsky, Y, Klein-Geltink, JE, Yates, EA, (eds). Atlas on the Primary Care of Adults with Developmental Disabilities in Ontario. Institute for Clinical Evaluative Sciences & Centre for Addiction and Mental Health, 2013.
2 Sheehan, R, Hassiotis, A, Walters, K, Osborn, D, Strydom, A, Horsfall, L. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ 2015; 351: h4326.
3 Cooper, S-A, Smiley, E, Morrison, J, Williamson, A, Allan, L. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry 2007; 190: 2735.
4 Morgan, VA, Leonard, H, Bourke, J, Jablensky, A. Intellectual disability co-occurring with schizophrenia and other psychiatric illness: population-based study. Br J Psychiatry 2008; 193: 364–72.
5 Brylewski, J, Duggan, L. Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database Syst Rev 2004; 3: CD000377.
6 Glover, G, Bernard, S, Branford, D, Holland, A, Strydom, A. Use of medication for challenging behaviour in people with intellectual disability. Br J Psychiatry 2014; 205: 67.
7 Teeluckdharry, S, Sharma, S, O'Rourke, E, Tharian, P, Gondalekar, A, Nainar, F, et al. Monitoring metabolic side effects of atypical antipsychotics in people with an intellectual disability. J Intellect Disabil 2013; 17: 223–35.
8 Frighi, V, Stephenson, MT, Morovat, A, Jolley, IE, Trivella, M, Dudley, CA, et al. Safety of antipsychotics in people with intellectual disability. Br J Psychiatry 2011; 199: 289–95.
9 Newcomer, JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68(Suppl 1): 20–7.
10 Nasrallah, HA. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry 2007; 68(Suppl 1): 511.
11 Azimi, K, Raina, P, Lunsky, Y. Brief report: occurrence of metabolic syndrome in patients with intellectual disability treated with atypical antipsychotics. J Dev Disabil 2011; 17: 4750.
12 Gazizova, D, Puri, BK, Singh, I, Dhaliwal, R. The overweight: obesity and plasma lipids in adults with intellectual disability and mental illness. J Intellect Disabil Res 2012; 56: 895901.
13 Lin, E, Balogh, R, Cobigo, V, Ouellette-Kuntz, H, Wilton, AS, Lunsky, Y. Using administrative health data to identify individuals with intellectual and developmental disabilities: a comparison of algorithms. J Intellect Disabil Res 2013; 57: 462–77.
14 Levy, AR, O'Brien, BJ, Sellors, C, Grootendorst, P, Willison, D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003; 10: 6771.
15 Juurlink, D, Preyra, C, Croxford, R, Chong, A, Austin, P, Tu, J, et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. Canadian Institute for Health Information, 2006.
16 Hirdes, JP, Smith, TF, Rabinowitz, T, Yamauchi, K, Perez, E, Telegdi, NC, et al. The Resident Assessment Instrument-Mental Health (RAI-MH): inter-rater reliability and convergent validity. J Behav Health Serv Res 2002; 29: 419–32.
17 Urbanoski, KA, Mulsant, BH, Willett, P, Ehtesham, S, Rush, B. Real-world evaluation of the Resident Assessment Instrument-Mental Health assessment system. Can J Psychiatry 2012; 57: 687–95.
18 Government of Ontario. Services and Supports to Promote the Social Inclusion of Persons with Developmental Disabilities Act, 2008 (https://www.ontario.ca/laws/statute/08s14). Government of Ontario, 2008.
19 American Association on Intellectual & Developmental Disabilities. Intellectual Disability: Definition, Classification, and Systems of Supports, 11th ed. American Association on Intellectual & Developmental Disabilities, 2011.
20 Quan, H, Khan, N, Hemmelgarn, BR, Tu, K, Chen, G, Campbell, N, et al. Validation of a case definition to define hypertension using administrative data. Hypertension 2009; 54: 1423–8.
21 Hux, JE, Ivis, F, Flintoft, V, Bica, A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002; 25: 512–6.
22 Tagalakis, V, Kahn, SR. Determining the test characteristics of claims-based diagnostic codes for the diagnosis of venous thromboembolism in a medical service claims database. Pharmacoepidemiol Drug Saf 2011; 20: 304–7.
23 The Johns Hopkins ACG System. Technical Reference Guide Version 9.0. Health Services Research & Development Center, Johns CHopkins University, Bloomberg USchool of Public Health, 2009.
24 Normand, ST, Landrum, MB, Guadagnoli, E, Ayanian, JZ, Ryan, TJ, Cleary, PD, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001; 54: 387–98.
25 Berry, SD, Ngo, L, Samelson, EJ, Kiel, DP. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc 2010; 58: 783–7.
26 Fine, JP, Gray, RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496509.
27 SAS Software. Version 9.3 of the SAS System for Unix. SAS Institute Incorporated, 2012.
28 Tsakanikos, E, Bouras, N, Sturmey, P, Holt, G. Psychiatric co-morbidity and gender differences in intellectual disability. J Intellect Disabil Res 2006; 50: 582–7.
29 Balogh, RS, Lake, JK, Lin, E, Wilton, A, Lunsky, Y. Disparities in diabetes prevalence and preventable hospitalizations in people with intellectual and developmental disability: a population-based study. Diabet Med 2015; 32: 235–42.
30 Lunsky, Y, Bradley, EA, Gracey, CD, Durbin, J, Koegl, C. Gender differences in psychiatric diagnoses among inpatients with and without intellectual disabilities. Am J Intellect Dev Disabil 2009; 114: 5260.
31 Matson, JL, Neal, D. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: an overview. Res Dev Disabil 2009; 30: 572–86.
32 Leucht, S, Bradley, EA, Gracey, CD, Durbin, J, Koegl, C. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 3141.
33 Merriman, S, Haw, C, Kirk, J, Stubbs, J. Risk factors for coronary heart disease among inpatients who have mild intellectual disability and mental illness. J Intellect Disabil Res 2005; 49: 309–16.
34 Valdovinos, M, Parsa, R, Alexander, M. Results of a Nation-Wide survey evaluating psychotropic medication use in Fragile X Syndrome. J Dev Phys Disabil 2009; 21: 2337.
35 Bhaumik, S, Watson, JM, Thorp, CF, Tyrer, F, McGrother, CW. Body mass index in adults with intellectual disability: distribution, associations and service implications: a population-based prevalence study. J Intellect Disabil Res 2008; 52: 287–98.
36 Tenenbaum, A, Chavkin, M, Wexler, ID, Korem, M, Merrick, J. Morbidity and hospitalizations of adults with Down syndrome. Res Dev Disabil 2012; 33: 435–41.
37 Humphries, K, Traci, MA, Seekins, T. Nutrition and adults with intellectual or developmental disabilities: systematic literature review results. Intellect Dev Disabil 2009; 47: 163–85.
38 de Winter, CF, Bastiaanse, LP, Hilgenkamp, TI, Evenhuis, HM, Echteld, MA. Cardiovascular risk factors (diabetes, hypertension, hypercholesterolemia and metabolic syndrome) in older people with intellectual disability: results of the HAID study. Res Dev Disabil 2012; 33: 1722–31.
39 Hagg, S, Spigset, O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002; 16: 765–76.
40 Moores, L, Bilello, KL, Murin, S. Sex and gender issues and venous thromboembolism. Clin Chest Med 2004; 25: 281–97.
41 Aichhorn, W, Whitworth, AB, Weiss, EM, Marksteiner, J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 2006; 29: 587–98.
42 de Kuijper, G, Mulder, H, Evenhuis, H, Scholte, F, Visser, F, Hoekstra, PJ. Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics. Res Dev Disabil 2013; 34: 2799–809.
43 Tyrer, P, Cooper, SA, Hassiotis, A. Drug treatments in people with intellectual disability and challenging behaviour. BMJ 2014; 349: g4323.
44 Baburaj, R, El Tahir, M. Monitoring for Metabolic Syndrome in People with Intellectual Disability on Antipsychotic Medication. Advances in Mental Health and Intellectual Disabilities, 2011.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Open
  • ISSN: -
  • EISSN: 2056-4724
  • URL: /core/journals/bjpsych-open
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 27 *
Loading metrics...

Abstract views

Total abstract views: 57 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 25th April 2018. This data will be updated every 24 hours.

Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs

  • Simone N. Vigod (a1), Yona Lunsky (a2), Virginie Cobigo (a3), Andrew S. Wilton (a4), Sarah Somerton (a5) and Dallas P. Seitz (a6)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *